

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Serial No.: 09/079,785

Filed: May 15, 1998

Date of Notice of Allowance: May 3, 2000

For: CD30 LIGAND OLIGOMERS AND POLYPEPTIDES



Docket No.: 2804-H

Group Art Unit: 1646

Examiner: L. Spector

Batch no.: L94

Handwritten signature/initials

**COMMENT ON EXAMINER'S COMMENT ATTACHED TO
NOTICE OF ALLOWABILITY**

BOX Issue Fee
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

To insure accuracy of the record, Applicants submit the following comment on the Examiner's comment presented on page two of the Attachment to Notice of Allowability (part of paper 11). The Examiner's comment notes acceptance and recordation of a terminal disclaimer that refers to U.S. Patent number 5,480,491. Applicants wish to point out that the terminal disclaimer in question refers to U.S. Patent number 5,480, 981 (not 5,480,491).

Respectfully submitted,

Handwritten signature of Kathryn A. Anderson

Immunex Corporation
51 University Street
Seattle, Washington 98101
(206) 389-4341 (direct line)

Kathryn A. Anderson
Registration No. 32,172

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX Issue Fee, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date:

July 28, 2000

Signed:

Camilla C. Edwards

Match and Return

DR
OK to Enter